share_log

三葉草及信達生物跌逾5% 百心安挫24% 百濟神州及騰盛博藥回升近3%至6%

AASTOCKS ·  Dec 2, 2022 15:15

內地出台第七批國家集採中選藥品涉60種平均降價48%後,醫藥板塊連續第二天榮辱互見。騰盛博藥-B(02137.HK)回落守穩20天線(8.17元),今天高見8.88元,現報8.75元,回升5.7%。百濟神州(06160.HK)盤中曾高見119.2元,現報118.2元,回升近3%。

藍籌中生製藥(01177.HK)回升1.6%曾高見4.58元。同為藍籌翰森製藥(03692.HK)和藥明生物(02269.HK)反覆續升1.1%及0.8%,報15元及51.05元。康希諾(06185.HK)及開拓藥業-B(09939.HK)反覆回升0.9%-1.7%,各報90.6元及12.86元。

相反,三葉草生物-B(02197.HK)兩連跌後,今天高低見4.87元/4.31元,現報4.46元,反覆續跌4.9%。信達生物(01801.HK)今日股價高低見30.8元/28元,現報28.1元,反覆續跌5.2%。康方生物(09926.HK)反覆回吐4%報32.4元,股價失守10天線(33.1元)。再鼎醫藥-B(09688.HK)及藥明康德(02359.HK)回吐1.7%-2.7%,各報28.3元及74.85元。

此外,內地創新介入式心血管裝置公司的百心安-B(02185.HK)兩連跌後,今日曾回升至14.02元無以為繼,掉頭再創上市新低,盤中曾低見8.65元,現報9.87元,續挫24%。

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment